US Stocks in Motion | Novo Nordisk (NVO.US) up 6% as Semaglutide receives extension of exclusivity in Chinese market

According to intelligent financial APP, on Monday, Novo Nordisk (NVO.US) rose 6% to $45.79. In terms of news, the CEO of Novo Nordisk recently clarified that the regulatory data protection period for the company's flagship product Semaglutide in China will continue until April 2027, more than a year later than the expiration date of its core compound patent (March 2026). It is estimated that this extended 13-month protection period could bring the company approximately $1 billion in additional stable cash flow.